OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

被引：0
|
作者：
Van Laethem, Jean-Luc
Borbath, Ivan
Geboes, Karen Paula
Cassier, Philippe Alexandre
Lambert, Aurelien
Mitry, Emmanuel
Prenen, Hans
Pilla, Lorenzo
Blanc, Jean-Frederic
Gallego Jimenez, Inmaculada
Cid, Roberto A. Pazo
Rodriguez Garrote, Mercedes
Feliu, Jaime
Nordbladh, Karin
Smith, Karin Enell
Gomez Jimenez, David
Ellmark, Peter
Pico de Coa, Yago
Ambarkhane, Sumeet Vijay
Macarulla, Teresa
机构：
[1] Erasme Univ Hosp, Brussels, Belgium
[2] St Luc Univ Clin, Brussels, Belgium
[3] Ghent Univ Hosp, Div Digest Oncol, Dept Gastroenterol, Ghent, Belgium
[4] Ctr Leon Berard, Lyon, France
[5] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[6] Inst Paoli Calmettes, Marseille, France
[7] Univ Hosp Gasthuisberg, Leuven, Belgium
[8] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Gastroenterol & Gastrointestinal Oncol, Paris, France
[9] Hop Haut Leveque, Pessac, France
[10] Hosp Univ Virgen Rocio, Seville, Spain
[11] Hosp Univ Miguel Servet, Zaragoza, Spain
[12] Hosp Univ Ramon y Cajal, Madrid, Spain
[13] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[14] Alligator Biosci AB, Lund, Sweden
[15] Vall Hebron Univ Hosp, Barcelona, Spain
[16] Vall Hebron Inst Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4133
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
    Kimmie Ng
    Andrew Hendifar
    Alexander Starodub
    Jorge Chaves
    Yingsi Yang
    Brian Koh
    David Barbie
    William C. Hahn
    Charles S. Fuchs
    Investigational New Drugs, 2019, 37 : 159 - 165
  • [22] Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
    Jiang, Haiping
    Zheng, Yulong
    Qian, Jiong
    Mao, Chenyu
    Xu, Xin
    Li, Ning
    Xiao, Cheng
    Wang, Huan
    Teng, Lisong
    Zhou, Hui
    Wang, Shuyan
    Zhu, Donglei
    Sun, Tao
    Yu, Yingying
    Guo, Wenying
    Xu, Nong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 857 - 868
  • [23] Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
    Haiping Jiang
    Yulong Zheng
    Jiong Qian
    Chenyu Mao
    Xin Xu
    Ning Li
    Cheng Xiao
    Huan Wang
    Lisong Teng
    Hui Zhou
    Shuyan Wang
    Donglei Zhu
    Tao Sun
    Yingying Yu
    Wenying Guo
    Nong Xu
    Cancer Immunology, Immunotherapy, 2021, 70 : 857 - 868
  • [24] Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1β and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).
    Oberstein, Paul Eliezer
    Rahma, Osama E.
    Beri, Nina
    Stoll-D'Astice, Amy C.
    Duliege, Anne-Marie
    Kawaler, Emily
    Dolgalev, Igor
    Werba, Gregor
    Cardot-Ruffino, Victoire
    Bollenrucher, Naima
    Nazeer, Saloney
    Squires, Matthew
    Bar-Sagi, Dafna
    Wolpin, Brian M.
    Dougan, Stephanie
    Simeone, Diane M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16287 - E16287
  • [25] CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
    O'Hara, Mark H.
    O'Reilly, Eileen M.
    Varadhachary, Gauri
    Wolff, Robert A.
    Wainberg, Zev A.
    Ko, Andrew H.
    Fisher, George
    Rahma, Osama
    Lyman, Jaclyn P.
    Cabanski, Christopher R.
    Mick, Rosemarie
    Gherardini, Pier Federico
    Kitch, Lacey J.
    Xu, Jingying
    Samuel, Theresa
    Karakunnel, Joyson
    Fairchild, Justin
    Bucktrout, Samantha
    LaVallee, Theresa M.
    Selinsky, Cheryl
    Till, Jacob E.
    Carpenter, Erica L.
    Alanio, Cecile
    Byrne, Katelyn T.
    Chen, Richard O.
    Trifan, Ovid C.
    Dugan, Ute
    Horak, Christine
    Hubbard-Lucey, Vanessa M.
    Wherry, E. John
    Ibrahim, Ramy
    Vonderheide, Robert H.
    LANCET ONCOLOGY, 2021, 22 (01): : 118 - 131
  • [26] Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
    Coveler, Andrew L.
    Gutierrez, Martin
    Vaccaro, Gina M.
    Brown-Glaberman, Ursa
    Grilley-Olson, Juneko E.
    Kindler, Hedy L.
    Zalupski, Mark
    Heath, Elisabeth I.
    Piha-Paul, Sarina A.
    Wehr, Allison
    Lu, Hailing
    Hayman, Jonathan
    Bajor, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 708 - 708
  • [27] Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
    Flinn, Ian W.
    Gribben, John G.
    Dyer, Martin J. S.
    Wierda, William G.
    Maris, Michael B.
    Furman, Richard R.
    Hillmen, Peter
    Jones, Jeffrey
    Iyer, Swami P.
    Jones, Surai
    Jiang, Yanwen
    Pignataro, Daniela Soriano
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kipps, Thomas J.
    BLOOD, 2017, 130
  • [28] Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.
    O'Hara, Mark H.
    O'Reilly, Eileen Mary
    Wolff, Robert A.
    Wainberg, Zev A.
    Ko, Andrew H.
    Rahma, Osama E.
    Fisher, George A.
    Lyman, Jaclyn Paige
    Cabanski, Christopher R.
    Karakunnel, Joyson Joseph
    Gherardini, Pier Federico
    Kitch, Lacey J.
    Bucktrout, Samantha
    Christopher, Elizabeth
    Mick, Rosemarie
    Chen, Richard
    Trifan, Ovidiu C.
    Salvador, Lisa
    O'Donnell-Tormey, Jill
    Vonderheide, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy
    O'Hara, Mark H.
    Wattenberg, Max
    Garrido-Laguna, Ignacio
    O'Reilly, Eileen M.
    Yellin, Michael
    Keler, Tibor
    Gargano, Michele
    Niles, Nick
    Drees, Jeremy
    Bose, Nandita
    Beatty, Gregory L.
    CANCER RESEARCH, 2024, 84 (17)
  • [30] Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)
    Hendifar, A.
    Bullock, A.
    Seery, T.
    Zheng, L.
    Sigal, D.
    Ritch, P. S.
    Braiteh, F. S.
    Zalupski, M.
    Bahary, N.
    Harris, W.
    Pu, J.
    Lian, F.
    Zhu, J.
    Wu, W.
    Chondros, D.
    Jiang, P.
    Hingorani, S. R.
    ANNALS OF ONCOLOGY, 2017, 28
12345